Ad Header



The Pulse of the Pharmaceutical Industry

GlaxoSmithKline: Offsetting Results

GlaxoSmithKline is succeeding with newly launched products and strong R&D flow while struggling with U.S. pricing and competitive pressures.

Read More »

2014 Annual Report: Top 50 Companies Overview – Back From The Brink

The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.

Read More »

Bristol-Myers Squibb: Shifting Gears

The last few months have seen two major shifts for Bristol-Myers Squibb – out of diabetes and into immuno-oncologics.

Read More »

AstraZeneca: Turning The Ship Around

AstraZeneca’s efforts to rebuild its pipeline and invest in its growth platforms attracted Pfizer’s notice, with an unsolicited bid of acquisition.

Read More »

Amgen: Move Over Big Pharma

Bolstered by company-record sales, innovative blockbuster products, successful M&A activity, and a pipeline of medicines with breakaway potential, Amgen becomes the first biotech entity to be recognized by Med Ad News as its Company of the Year.

Read More »

Teva Pharmaceutical Industries: A Rebuilding Year

The world’s largest generics company has emerged from the past year with a new CEO, a new organizational structure, and a newly improved bottom line.

Read More »

Sanofi: Defense In Depth

Sanofi is trying to bounce back from 2013’s patent cliff with the help of one of the industry’s most diverse product portfolios.

Read More »

Roche: Positive Growth Trends

Concentration on targeted medicines and diagnostic tests has enabled Roche to expand its strong market position and significantly improve net income.

Read More »

Special Feature: The Power Of Networks

For many women who want to advance to leadership in the pharmaceutical industry, the HBA provides the essential tools, backed by its members and corporate partners.

Read More »

Pfizer: A Giant Stumbles

Pfizer stuck to its priorities, but the company’s attempt to buy AstraZeneca fell flat.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom